Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Mar 25, 2026

Noninvasive Assessment of Cardiac Abnormalities in Experimental Autoimmune Myocarditis by Magnetic Resonance Microscopy Imaging in the Mouse
12:24

Noninvasive Assessment of Cardiac Abnormalities in Experimental Autoimmune Myocarditis by Magnetic Resonance Microscopy Imaging in the Mouse

Published on: June 20, 2014

10.5K

Mesalamine-induced myopericarditis - A case report.

Sónia Bernardo1, Samuel Raimundo Fernandes2, Luís Araújo-Correia1

  • 1Serviço de Gastrenterologia e Hepatologia, Hospital Santa Maria, Portugal.

Revista Espanola De Enfermedades Digestivas
|February 16, 2016
PubMed
Summary

Mesalamine can cause myopericarditis, a rare heart condition, in patients with inflammatory bowel disease. Discontinuing the drug led to full recovery, highlighting the importance of considering this side effect in patients with cardiac symptoms.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transmural improvement may be an acceptable target in patients with Crohns disease.

Inflammatory bowel diseases·2026
Same author

Fecal calprotectin-guided treatment escalation strategy enhances disease clearance in ulcerative colitis.

European journal of gastroenterology & hepatology·2026
Same author

IBD-PODCAST Portugal: Proportion of Patients with Suboptimal Disease Control and Its Impact on Quality of Life in Inflammatory Bowel Disease.

GE Portuguese journal of gastroenterology·2025
Same author

Treat-to-Target in Inflammatory Bowel Disease: An Updated Survey of Treatment Strategies among Portuguese Gastroenterologists.

GE Portuguese journal of gastroenterology·2025
Same author

EVOLVE-IBERIA: Real-world evidence on vedolizumab and anti-tumor necrosis factor-α as first- or second-line biologic treatment among patients with ulcerative colitis.

Gastroenterologia y hepatologia·2025
Same author

Early Top-Down Treatment With Biologics Improves the Rates of Transmural Remission in Crohn's Disease-A Risk-Adjusted Propensity Score Matched Analysis.

Inflammatory bowel diseases·2025

Area of Science:

  • Cardiology
  • Gastroenterology
  • Pharmacology

Background:

  • Mesalamine is a common treatment for inflammatory bowel disease.
  • Myopericarditis is a known, though infrequent, adverse effect of mesalamine therapy.

Observation:

  • A 20-year-old female patient with ulcerative colitis presented with chest pain.
  • Diagnostic workup revealed myopericarditis, suspected to be linked to mesalamine use.

Findings:

  • The patient experienced complete clinical and laboratory recovery after mesalamine withdrawal.
  • This case supports a potential causal relationship between mesalamine and myopericarditis.

Implications:

  • Clinicians should consider mesalamine-induced myopericarditis in inflammatory bowel disease patients with cardiac symptoms.

Related Experiment Videos

Last Updated: Mar 25, 2026

Noninvasive Assessment of Cardiac Abnormalities in Experimental Autoimmune Myocarditis by Magnetic Resonance Microscopy Imaging in the Mouse
12:24

Noninvasive Assessment of Cardiac Abnormalities in Experimental Autoimmune Myocarditis by Magnetic Resonance Microscopy Imaging in the Mouse

Published on: June 20, 2014

10.5K
  • Early diagnosis and discontinuation of mesalamine can prevent severe cardiac complications.